These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 22609427

  • 1. Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis-Part II: in vivo assessment of dermatopharmacokinetics, biodistribution and efficacy.
    Pople PV, Singh KK.
    Int J Pharm; 2012 Sep 15; 434(1-2):70-9. PubMed ID: 22609427
    [Abstract] [Full Text] [Related]

  • 2. Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis.
    Pople PV, Singh KK.
    Int J Pharm; 2010 Oct 15; 398(1-2):165-78. PubMed ID: 20637847
    [Abstract] [Full Text] [Related]

  • 3. Development and evaluation of colloidal modified nanolipid carrier: application to topical delivery of tacrolimus, Part II--in vivo assessment, drug targeting, efficacy, and safety in treatment for atopic dermatitis.
    Pople PV, Singh KK.
    Eur J Pharm Biopharm; 2013 May 15; 84(1):72-83. PubMed ID: 23246619
    [Abstract] [Full Text] [Related]

  • 4. Tacrolimus-loaded ethosomes: physicochemical characterization and in vivo evaluation.
    Li G, Fan Y, Fan C, Li X, Wang X, Li M, Liu Y.
    Eur J Pharm Biopharm; 2012 Sep 15; 82(1):49-57. PubMed ID: 22705640
    [Abstract] [Full Text] [Related]

  • 5. Development and evaluation of colloidal modified nanolipid carrier: application to topical delivery of tacrolimus.
    Pople PV, Singh KK.
    Eur J Pharm Biopharm; 2011 Sep 15; 79(1):82-94. PubMed ID: 21447390
    [Abstract] [Full Text] [Related]

  • 6. Safer than safe: lipid nanoparticulate encapsulation of tacrolimus with enhanced targeting and improved safety for atopic dermatitis.
    Singh KK, Pople P.
    J Biomed Nanotechnol; 2011 Feb 15; 7(1):40-1. PubMed ID: 21485793
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis.
    Singalavanija S, Noppakun N, Limpongsanuruk W, Wisuthsarewong W, Aunhachoke K, Chunharas A, Wananukul S, Akaraphanth R.
    J Med Assoc Thai; 2006 Nov 15; 89(11):1915-22. PubMed ID: 17205874
    [Abstract] [Full Text] [Related]

  • 8. Dermatophagoides farinae extract induces severe atopic dermatitis in NC/Nga mice, which is effectively suppressed by the administration of tacrolimus ointment.
    Oshio T, Sasaki Y, Funakoshi-Tago M, Aizu-Yokota E, Sonoda Y, Matsuoka H, Kasahara T.
    Int Immunopharmacol; 2009 Apr 15; 9(4):403-11. PubMed ID: 19162238
    [Abstract] [Full Text] [Related]

  • 9. Tacrolimus ointment (Protopic) for atopic dermatitis.
    Pascual JC, Fleisher AB.
    Skin Therapy Lett; 2004 Nov 15; 9(9):1-5. PubMed ID: 15550992
    [Abstract] [Full Text] [Related]

  • 10. Tacrolimus nanoparticles based on chitosan combined with nicotinamide: enhancing percutaneous delivery and treatment efficacy for atopic dermatitis and reducing dose.
    Yu K, Wang Y, Wan T, Zhai Y, Cao S, Ruan W, Wu C, Xu Y.
    Int J Nanomedicine; 2018 Nov 15; 13():129-142. PubMed ID: 29317821
    [Abstract] [Full Text] [Related]

  • 11. Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment.
    Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU.
    J Allergy Clin Immunol; 2004 Oct 15; 114(4):887-95. PubMed ID: 15480330
    [Abstract] [Full Text] [Related]

  • 12. Tacrolimus pharmacology and nonclinical studies: from FK506 to protopic.
    Bekersky I, Lilja H, Lawrence I.
    Semin Cutan Med Surg; 2001 Dec 15; 20(4):226-32. PubMed ID: 11770909
    [Abstract] [Full Text] [Related]

  • 13. Topically applied semaphorin 3A ointment inhibits scratching behavior and improves skin inflammation in NC/Nga mice with atopic dermatitis.
    Negi O, Tominaga M, Tengara S, Kamo A, Taneda K, Suga Y, Ogawa H, Takamori K.
    J Dermatol Sci; 2012 Apr 15; 66(1):37-43. PubMed ID: 22381253
    [Abstract] [Full Text] [Related]

  • 14. In-vivo dermal pharmacokinetics, efficacy, and safety of skin targeting nanoparticles for corticosteroid treatment of atopic dermatitis.
    Siddique MI, Katas H, Amin MC, Ng SF, Zulfakar MH, Jamil A.
    Int J Pharm; 2016 Jun 30; 507(1-2):72-82. PubMed ID: 27154252
    [Abstract] [Full Text] [Related]

  • 15. Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis.
    Dähnhardt-Pfeiffer S, Dähnhardt D, Buchner M, Walter K, Proksch E, Fölster-Holst R.
    J Dtsch Dermatol Ges; 2013 May 30; 11(5):437-43. PubMed ID: 23551950
    [Abstract] [Full Text] [Related]

  • 16. Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study.
    Marsella R, Nicklin CF, Saglio S, Lopez J.
    Vet Dermatol; 2004 Oct 30; 15(5):294-303. PubMed ID: 15500481
    [Abstract] [Full Text] [Related]

  • 17. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
    Hultsch T, Kapp A, Spergel J.
    Dermatology; 2005 Oct 30; 211(2):174-87. PubMed ID: 16088174
    [Abstract] [Full Text] [Related]

  • 18. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis.
    Schuller E, Oppel T, Bornhövd E, Wetzel S, Wollenberg A.
    J Allergy Clin Immunol; 2004 Jul 30; 114(1):137-43. PubMed ID: 15241357
    [Abstract] [Full Text] [Related]

  • 19. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis.
    Lapteva M, Mondon K, Möller M, Gurny R, Kalia YN.
    Mol Pharm; 2014 Sep 02; 11(9):2989-3001. PubMed ID: 25057896
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.